Diabetic macular oedema (DMO) is a primary vision threatening complication of diabetic retinopathy, with many studies supporting the role that anti-vascular endothelial growth factor (anti-VEGF) therapy plays in its management [3–5]. The gene discussed is VEGFA; the disease is diabetic retinopathy.